Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Citalopram Hydrobromide

FDA-approved product (tablet, oral), marketed as Celexa, Citalopram Hydrobromide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Citalopram Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Citalopram Hydrobromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Citalopram Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Hydroxyzine for Patients With Panic Disorder

    NCT05737511 · start 2023-12-30

    Registered record
    Registry ID
    NCT05737511
    Conditions
    Panic Disorder
    Interventions
    Hydroxyzine; Escitalopram Oxalate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2023-12-30
    Completion
    2026-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    InterventionHydroxyzine; Escitalopram Oxalate
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

    NCT06049797 · start 2023-11-15

    Registered record
    Registry ID
    NCT06049797
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Paroxetine; Citalopram; Escitalopram; Desvenlafaxine; Venlafaxine; Gabapentin; Clonidine; Pregabalin; Oxybutynin; Any other SSRI/SNRI not already specified; Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-11-15
    Completion
    2026-05-07
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Paroxetine; Citalopram; Escitalopram +8 more
    PhaseNot recorded
    Registry statusCompleted

  • Human Cerebral Blood Flow and Serotonin

    NCT05957094 · start 2023-08

    Registered record
    Registry ID
    NCT05957094
    Conditions
    Depression; Serotonin Deficiency
    Interventions
    Pharmacological agent: Citalopram; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-08
    Completion
    2024-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Serotonin Deficiency
    InterventionPharmacological agent: Citalopram; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

    NCT05952713 · start 2022-10-01

    Registered record
    Registry ID
    NCT05952713
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-07-01
    Enrolment
    73,336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant
    PhaseNot recorded
    Registry statusCompleted

  • Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.

    NCT05795283 · start 2022-08-01

    Registered record
    Registry ID
    NCT05795283
    Conditions
    Anorexia Nervosa
    Interventions
    Citalopram i.v. and p.o; Citalopram p.o
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-08-01
    Completion
    2024-08-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa
    InterventionCitalopram i.v. and p.o; Citalopram p.o
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

    NCT05735756 · start 2022-01-17

    Registered record
    Registry ID
    NCT05735756
    Conditions
    Functional Chest Pain
    Interventions
    Citalopram 20mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-01-17
    Completion
    2022-04-22
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFunctional Chest Pain
    InterventionCitalopram 20mg; Placebo
    PhasePhase 4
    Registry statusTerminated

  • SSRIs and TDCS Enhance Post-stroke Motor Recovery

    NCT05041582 · start 2021-09-01

    Registered record
    Registry ID
    NCT05041582
    Conditions
    Stroke; Motor
    Interventions
    tDCS; Citalopram; Rehabilitation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2025-08-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Motor
    InterventiontDCS; Citalopram; Rehabilitation
    PhasePhase 3
    Registry statusUnknown

  • Electronic Training of Elderly Depression With Cognitive Impairment

    NCT05588102 · start 2021-05-18

    Registered record
    Registry ID
    NCT05588102
    Conditions
    Geriatric Depression; Cognitive Impairment
    Interventions
    Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-05-18
    Completion
    2023-08-01
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeriatric Depression; Cognitive Impairment
    InterventionSelective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）
    PhaseNot applicable
    Registry statusCompleted

  • Myofascial Pain Patients' Response to the Administration of Low Doses of Amitriptyline and Citalopram Compared With the Use of Bite Splint

    NCT04777838 · start 2021-03

    Registered record
    Registry ID
    NCT04777838
    Conditions
    Muscle Type Temporomandibular Disorders; Myofascial Pain of the Masticatory Muscles
    Interventions
    Citalopram 10 MG; Amitriptyline; Bite Splint
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-03
    Completion
    2021-05
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMuscle Type Temporomandibular Disorders; Myofascial Pain of the Masticatory Muscles
    InterventionCitalopram 10 MG; Amitriptyline; Bite Splint
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Comparison of Fluoxetine Versus Citalopram Therapy to Control Postmenopausal Vasomotor Syndrome

    NCT05346445 · start 2021-01-20

    Registered record
    Registry ID
    NCT05346445
    Conditions
    Postmenopause; Hot Flashes
    Interventions
    Fluoxetine 20 MG; Citalopram 20mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-20
    Completion
    2021-12-20
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause; Hot Flashes
    InterventionFluoxetine 20 MG; Citalopram 20mg
    PhaseNot applicable
    Registry statusCompleted

  • Improving Quality of Life in Early Parkinson's Disease

    NCT04590612 · start 2021-01

    Registered record
    Registry ID
    NCT04590612
    Conditions
    Parkinson Disease; Depression
    Interventions
    Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet; Citalopram
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-01
    Completion
    2022-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Depression
    InterventionCarbidopa-Levodopa 25 Mg-100 Mg Oral Tablet; Citalopram
    PhaseNot applicable
    Registry statusUnknown

  • Gustatory Modulators Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy

    NCT04923425 · start 2020-02-22

    Registered record
    Registry ID
    NCT04923425
    Conditions
    Taste Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-22
    Completion
    2020-10-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaste Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder

    NCT04975724 · start 2019-04-18

    Registered record
    Registry ID
    NCT04975724
    Conditions
    Major Depressive Disorder
    Interventions
    Liposom Forte; Citalopram; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04-18
    Completion
    2025-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionLiposom Forte; Citalopram; Placebo
    PhasePhase 4
    Registry statusUnknown

  • A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

    NCT03907215 · start 2019-04-09

    Registered record
    Registry ID
    NCT03907215
    Conditions
    Healthy
    Interventions
    ACT541468; ACT541468 placebo; Citalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-09
    Completion
    2019-06-26
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionACT541468; ACT541468 placebo; Citalopram
    PhasePhase 1
    Registry statusCompleted

  • Predicting Treatment Response in Patients With OCD

    NCT03993535 · start 2018-10-10

    Registered record
    Registry ID
    NCT03993535
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    selective serotonin reuptake inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-10-10
    Completion
    2023-04-30
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    Interventionselective serotonin reuptake inhibitor
    PhasePhase 4
    Registry statusCompleted